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Abstract: Extracellular vesicles (EVs) are composed of bilayer membranes that are released by
different cell types and are present in bodily fluids, such as blood, urine, and bile. EVs are thought to
play a key role in intracellular communication. Based on their size and density, EVs are classified
into small, medium, or large EVs. Cargo composition in EVs reflects physiological changes in health
and disease. Patients with irritable bowel syndrome (IBS) exhibit visceral hypersensitivity and
mood disorders. Stressful episodes often precede disease symptoms in IBS patients. Stress-induced
symptoms include, but are not limited to, abdominal pain and mood swings. Perceived stress
responses are mediated by two known G protein-coupled receptors (GPCRs), corticotropin-releasing
factor receptor 1 and 2 (CRFRs). CRFRs belong to the Class B secretin receptor family of GPCRs.
Here, we show that CRFRs were present in human and murine plasma, and in EVs purified from
mouse serum. CRFRs were present in plasma from IBS patients and healthy controls. EVs secreted
from immune cells influence both adaptive and innate immune responses via exchange of EVs
between different immune cell types. B7-2 (CD86), a plasma membrane antigen-presenting protein, is
present on EVs secreted from dendritic, B-, and mast cells, whereas CD9 is present on EVs secreted
from dendritic and intestinal epithelial cells. We found that plasma CRFR levels positively correlated
with B7-2+ EVs (R = 0.8597, p < 0.0001), but no association was seen with CD9+ EVs. Plasma CRFRs
expression negatively correlated with IBS severity scores. Our data suggests that plasma EVs from
immune cells carry CRFRs as cargos and influence cell-cell communication in health and disease.
Keywords: cell-to-cell; B-cells; dendritic cells; EV cargo
1. Introduction
Extracellular vesicles (EVs) are composed of bilayer membranes that are released by different
cell types. Based on their biogenesis, size, or densities, EVs are classified into different categories [1].
EVs formed from the membranes of intracellular compartments via the endocytic pathways are
referred to as exosomes. Exosomes range from 50–100 nm in diameter with buoyant densities of
1.11–1.19 g/mL [1]. Microvesicles that originate from the outward blebbing of the plasma membrane
are often referred to as ectosomes or microparticles and range from 100–1000 nm in diameter. The recent
guidelines posted by the International Society for Extracellular Vesicles recommends referring to EVs
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based on their size and densities as small (sEVs), medium, and large (m/lEVs) EVs [2]. EVs are involved
in the regulation of a myriad of biological activities, from pro-coagulant to immunomodulation,
including tissue repair and remodeling [3]. EVs are being explored as potential biomarkers, drug
candidates, drug carriers, or therapeutic targets.
In cultured inner medullary collecting duct (IMCD3) kidney cells, actin-dependent machinery
regulates ectosome release from the tip of the cilia. These ectosomes contain G protein-coupled
receptors (GPCRs) that fail to migrate from cilia back into the cell [4]. In HEK293 cells, EVs have
been shown to contain GPCR heteromers that can be transported between cells [5]. Immune cells can
exchange EVs, thereby influencing both innate and adaptive immune responses [6]. T-cell activation
can be induced by dendritic cell-secreted EVs that express co-stimulatory molecules, such as CD80
(B7-1) and CD86 (B7-2), or directly by EVs derived from ICAM-1-presenting mature dendritic cells [7,8].
Chemokines and cytokines secreted into the blood by T-cells and monocytes are largely present in
EVs [9] and greater than 50% of cytokines secreted from the placental villous tissue are in soluble form,
where those secreted by amnion were largely EV-associated [9]. Other bodily fluids and tissues secrete
cytokines as a combination of EV-associated or soluble forms. Whether a given cytokine will be present
in free-form or EV-associated depends on the source of origin, thereby contributing to heterogeneity.
Irritable bowel syndrome (IBS), a gut-brain disorder, is classified into three subgroups diarrhea
predominant (IBS-D), constipation predominant (IBS-C), and mixed bowel habit (IBS-M) [10].
IBS patients report heightened visceral sensitivity and often suffer from mood disorders.
The hypothalamic-adrenal-pituitary (HPA) axis, the system at the core of the stress response, is involved
in the modulation of mood behavior. The classic “flight or fight” stress response involves the actions
of the corticotropin-releasing factors (CRF) system. The CRF family is comprised of four known
agonists, CRF, and three urocortins (UCN1-3), and two known G protein-coupled receptors (GPCRs),
CRF1 and CRF2. CRF1 activation initiates HPA responses and anxiety-like behavior, whereas CRF2
activation brings systems back to homeostasis, and mediates anxiolytic behavior [11,12]. We have
shown that CRF2 plays a vital role in mediating metabolic [13] and immune responses [14–19].
CRF2 receptor dysfunction is known to exacerbate edema, necrosis, and delayed healing [14,20].
Psychological stressors downregulate expression of CRF2 receptors [21] and CRF2 receptor null mice
(Crhr2−/−) are more anxious than wild-type littermates [22,23]. CRFRs modulate immune function
and permeability in the gut [15,24,25]. The CRF system also modulates visceral hypersensitivity [26]
and gut motility in animal models of stress [27]. It is also implicated in the modulation of gut motility
and mood behavior in IBS patients [28]. We previously documented increased levels of CRFRs in
duodenal biopsies of patients with Crohn’s disease [15], but the status of CRFRs in IBS patients
is unknown.
CRFRs belong to the Class B secretin receptor family of GPCRs. Various cell-types and tissues
synthesize and express CRFR [15,16,18,24,29,30]. CRFR mediate both autocrine and paracrine
responses [31], and thus, it is reasonable to speculate that they might be secreted in to the circulation
from various cells and tissues. However, the presence of CRFRs in plasma or EVs has not been shown
before. Depending on their origin, CRFRs might be secreted in free form or be EV-associated.
Human EVs are known to contain cytokines, microRNAs, specialized lipid, and proteins [32].
The EV lipid and cargo composition can substantially differ from that of the parental cells, from which
EVs originate. EVs are known to change dynamically in number and cargo content in response to
physiologic and pathophysiologic milieu [33]. EVs are present in many tissues and bodily fluids.
Increased concentration of EVs in bile associates significantly with biliary stenoses and has been
proposed as potential markers [34]. EVs present in blood have been studied intensely, but EVs in blood
of patients with gut-brain disorders, including IBS patients, have not been reported. Here, we report
the presence of stress receptors, CRFRs, in plasma of IBS-D patients and age-and sex-matched healthy
controls. Plasma CRFRs in conjunction with B7-2+ EVs that might originate from immune cells are
potential novel markers for IBS severity and important for cell-to-cell communication contributing to
IBS pathogenesis.
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2. Materials and Methods
2.1. Human Subjects
Study approval was obtained from the University of California, San Francisco (UCSF, IRB#
12-09375) and University of California, Los Angeles (UCLA, IRB# 12-001731) Institutional Review
Boards (IRBs). Subject recruitment at UCSF: UCSF IRB approved the retrospective analysis of these
samples and data and a waiver of consent was granted. All control subjects (n = 8; 4/sex) underwent
endoscopies for gastrointestinal symptoms (such as abdominal pain), but had no clinical or laboratory
findings to support a diagnosis of IBS or inflammatory bowel disease (IBD), as shown in Supplementary
Table S1. Patients with any previously diagnosed autoimmune or inflammatory conditions (such as
arthritis, thyroiditis, celiac, diabetes, and others) were excluded. Pathology blocks were obtained
and paraffin-embedded sections were stained for CRF receptor immunoreactivity, as described below.
Subject recruitment at UCLA: Male and female Rome III-positive IBS patients [10,35] and healthy
controls (HC) between the ages of 18 and 55 participated in the study. Current IBS symptom severity
was measured using the validated IBS Severity Scoring System (IBS-SS, Table 1) [36], and usual
severity was measured as none, mild, moderate, and severe [37]. We selected a homogenous patient
population (IBS-D) that was age and sex matched to healthy controls; IBS-D patients did not have
active psychiatric disease and were not on any prescription medications. Human blood samples were
collected in heparin vacutainer at UCLA between August 2013 and April 2017 after informed consent
was obtained. Cell debris and platelets were removed from plasma samples by centrifuging it 1500× g
for 15 min as per the manufacturer’s specifications, and aliquots were stored at −80 ◦C until further
analysis. Our IBS-D patients and healthy controls were well matched and blood samples collected and
processed in an identical manner. Thus, sample variability should be the minimum.
2.2. Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC
approval # AN177899-01) at UCSF and were conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. Crhr2−/− (C57BL/6 background) mice were a
generous gift from Dr. Mary Stenzel-Poore, Oregon Health Sciences University. The mice were housed
in a room that was temperature (22–25 ◦C) and light (12-h: 12-h light/dark cycle starting at 7:00 AM)
controlled. Mice had ad libitum access to standard Purina chow and water and were handled daily to
avoid handling act as a stressor. Crhr2+/− (heterozygous) mice were bred to obtain wild-type (WT) and
Crhr2−/− littermates. Serum and/or plasma from WT and Crhr2−/− littermates were used for detection
of EVs and serum was used to purify EVs.
2.3. Chemicals and Antibodies
All chemicals used were molecular biology grade and from known vendors. The following
primary and secondary antibodies were used in this study: CRF-RI/II (Santa Cruz Biotechnology,
Dallas, TX, USA; sc-1757; goat polyclonal; 1:1000; recognizes both CRF1 and CRF2 receptors), CRF-RI
(Santa Cruz Biotechnology; sc-12381; goat polyclonal; 1:1000) B7-2 (Santa Cruz Biotechnology; sc-19617;
mouse monoclonal; 1:1000), and CD9 (Santa Cruz Biotechnology; sc-13118; mouse monoclonal; 1:1000).
For Western blot analyses, secondary antibodies used were goat anti-mouse conjugated to Alexa Fluor
680 (Invitrogen Inc., Carlsbad, CA, USA) and goat anti-rabbit conjugated to IRDye 800 (Rockland
Immunochemicals, Pottstown, PA, USA) (both used at 1:20,000).
2.4. Extracellular Vesicles Isolation
Extracellular vesicles (EVs) were isolated using ExoQuick exosome precipitation kit (System
Biosciences, Palo Alto, CA, USA) according to the manufacturer’s specifications [38,39]. Briefly, 100 µL
of serum was mixed thoroughly with 25.2 µL of ExoQuick exosome precipitation solution and
incubated for 30 min at 4 ◦C. The mixture was centrifuged at 1500× g for 30 min, supernatant
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collected, and re-centrifuged at 1500× g for 5 min. EV pellets were resuspended in PBS, and total
protein concentration was measured using BCA assay (Bio-Rad, Hercules, CA, USA). Six (6) µg of
purified EVs per lane were used for immunoblotting. Several factors can influence the use of EVs as
biomarkers [40]. The viscosity of bodily fluids can be highly variable, which may affect EVs purity and
yield [1,40]. Factors such as age, sex, ethnicity, body mass index, disease, use of medications, general
lifestyle, and dietary habits can all influence EV yield and purity.
2.5. Western Blot Analysis
Mice and human plasma were diluted to 1:100 with PBS. Diluted plasma (10 µL) and exosomes
(5 µg) were heated at 80 ◦C for 10 min in sample loading buffer (0.5M Tris-Hcl [pH 6.8], 99% Glycerol,
SDS, Bromophenol Blue), resolved on a 10% SDS-PAGE, and transferred to polyvinylidene difluoride
membranes (PVDF, Immobilon-FL; Millipore, Billerica, MA, USA). The membranes were blocked
for 1 h at room temperature (Odyssey Blocking Buffer; Li-COR Biosciences, Lincoln, NE, USA) and
incubated with simultaneously with two primary antibodies at a time for 2 h at room temperature
(CRF-RI/II and B7-2 or CRF-RI/II and CD9). Membranes were washed for 30 min × 3 (1x PBS,
0.1% Tween20) and incubated with appropriate secondary antibodies for 1 h at room temperature.
Blots were visualized and bands quantified using the Odyssey Infrared Imaging System (Li-COR
Biosciences). However, for densitometric analysis of each band/antibody, the colors were separated
using a software program that is part of Odyssey’s Li-COR. For quantification of individual bands
from immunoblots, the densitometric analysis was done using the Li-COR software by drawing boxes
of the same size/area around the bands.
2.6. Immunohistochemistry
Immunohistochemistry was performed, as described previously [15]. Five-micron sections
from paraffin-embedded biopsy samples were obtained from the duodenum and the colon [15].
Sections were de-paraffinized in xylene and rehydrated in ethanol series and antigen retrieval was
performed by the heat method. Sections were incubated with primary antibodies (anti-CRF-RI/II)
overnight at 4 ◦C, washed, and incubated with fluorescent secondary antibodies (conjugated to FITC)
for 1 h at room temperature. Confocal images were captured on a Zeiss LSM Meta 510 confocal
microscope using Plan-Apochrom at 40× or 63× oil immersion objectives (NA 1.4). Omission of
primary antibody served as negative control.
2.7. Statistical Analysis
Statistical analysis was performed using the Prism v7.0 software (GraphPad Software Inc., La
Jolla, CA, USA). Two-way ANOVA was used to analyze main effects and interactions between groups.
When main effects were significant, Sidak’s multiple comparisons test was used to compare four
groups. Tukey’s multiple comparisons test was used to compare CRFR expressions between three
usual scores (Severity; Mild, Moderate and Severe). Differences with p < 0.05 were considered
statistically significant. Data are shown as mean ± standard error of mean (SEM).
3. Results
3.1. CRF Receptors are Present in Human Plasma
The presence of GPCRs in circulation is a novel and powerful concept. We first determined
that CRFRs were present in human plasma from healthy individuals and patients with IBS-D.
Immunoblot of diluted (1:100) serum samples revealed the presence of multiple CRFR bands; six
distinct band sizes for were observed (Figure 1a). CRFRs are known to be post-translationally modified,
as well as forming heteromers, and thus appear at multiple sizes [41]. Presence of B7-2 bands were
also noted, including at its expected size of ~75KDa (Figure 1a). Interestingly, anti-B7-2 (Figure 1b) and
anti-CD9 (Figure 1c) also showed multiple bands, including bands that overlapped with CRFR bands
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5 and 6, suggesting that EVs that express anti-B7-2 and CD-9 might carry cargos of varying sizes and
densities, including CRFRs.
3.1.1. CRF Receptors Are Present in Human Gut
We have recently shown presence of CRF receptors on mast cells [18], enteric neurons, pancreatic
acinar cells [16], and fibroblasts [29]. We have also shown increased mast cell infiltration in the gut in a
rat model of functional dyspepsia, a gut-brain disorder [19]. While presence of CRF receptors has been
shown in colonic tissues of patients with Crohn’s disease [15], it is not known if CRF receptors are also
expressed in other gut regions in healthy human subjects. Furthermore, while CRF2 receptor transcripts
are reported, presence of CRF1 receptor in different gut regions is controversial. We reasoned that
goblet cells are secretory and release contents into circulation, thus, might be another potential source
for secreted CRFRs. Confocal microscopy confirmed that CRFRs were present as punctate bodies in
the goblet cells in human duodenal and colonic biopsies (Figure 1d,e). These data suggest that CRFR
protein is present in the gut and the protein can both be made locally or secreted from these gut cells
into circulation either in free-form or as EV cargo. Since IBS-D patient show visceral hypersensitivity,
it is possible that CRFRs released from the goblet cells of IBS patients might have altered function.
3.1.2. CRF Receptors Are Present in Mouse Plasma and Purified EVs
Next, we reasoned that if CRF2 receptors are secreted in circulation, then plasma from CRF2
receptor knockout mice (Crhr2−/−) should not carry any detectable CRF2 receptors, but would still
express CRF1 receptors, whereas plasma from wild-type (WT) mice should express both CRFRs.
Immunoblotting revealed the presence of multiple CRFR bands in plasma from wild-type, but not
Crhr2−/− mice (Figure 2). Importantly, actin, a housekeeping protein, was present in plasma samples
from both WT and Crhr2−/− mice (Supplementary Figure S1). Most GPCRs appear as smears on
immunoblots or exist as multiple bands due to several post-translational modifications. We have shown
that CRFRs can exist as heteromers manifested as multiple bands, whereas individually transfected
CRF1 receptors show only subsets of bands [41]. We next performed immunoblot on plasma from WT
and Crhr2−/− mice using a CRF1 receptor antibody. In agreement with previous published studies,
this CRF1-specific antibody detected three bands in mouse plasma (Supplementary Figure S2).
To ascertain that CRFRs are secreted into blood as EV cargoes, EVs from mice serum were purified,
and EV markers anti-B7-2 and anti-CD9 [42] were used to confirm identity. B7-2, a plasma membrane
antigen-presenting protein is present on EVs secreted from immune cells including dendritic, B-,
and mast cells, whereas CD9 is present on EVs secreted from dendritic and intestinal epithelial
cells [42]. B7-2 and CD9 were chosen as markers of EVs, because CRFRs are present in immune
and intestinal cells, respectively. CRFRs in purified EVs co-localized with B7-2, but not CD9 bands.
CRFR expression in EVs from Crhr2−/− mice was considerably reduced (Figure 2).
3.1.3. CRF Receptors Are Present in Plasma of Patients with Irritable Bowel Syndrome (IBS) and
Associate with EVs and Disease Severity Scores
In plasma from IBS-D patients and healthy controls (HC) (n = 60, demographic and IBS severity
described in Table 1), six distinct CRFR bands were detected, as seen for mouse plasma. Two of the six
CRFR bands overlapped with B7-2+ and CD9+ EVs (Figure 1a–c). CRFR bands 5–6 that overlapped
with B7-2 showed a strong positive association (R = 0.8597, p < 0.0001, Figure 3a). Interestingly, CRFR
bands 5–6 showed no association with CD9 (R = 0.0793, p = 0.5452, Figure 3b). These data suggest
that specific immune cells secrete CRFR in EVs. CRFR bands 5–6 in human plasma that overlapped
with B7-2 showed a negative correlation with IBS Severity Score (R = 0.434, p = 0.0165, Figure 3c) and
disease severity (mild, moderate vs. severe, p = 0.013, Figure 3d). Criteria for IBS Severity Score [36]
and disease severity [37] has been described in these earlier publications. No statistically significant
main effect or interaction between IBS and sex or IBS and CRFR bands 5–6 was seen (Figure 3e).
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3.1.4. Plasma CRF Receptor Levels Associate with IBS Disease, but Not Sex
Women are twice as likely to suffer from IBS than men. IBS patients show visceral hypersensitivity,
and CRF system is involved in the regulation of visceral pain. We tested whether CRF receptor
expression was different between healthy individuals and those with IBS and whether sex was a
biological variable. Two-way ANOVA showed significant main effect of disease (IBS) on expression of
CRFR band 1 (F (1,56) = 13.3; p = 0.0006), but surprisingly, no interaction between IBS and sex was
noted (Figure 4a). Expression levels of CRFR band 1 were significantly higher in IBS vs. HC. Levels in
male and female IBS-D patients were higher compared with male HC (Figure 4a). Total CRFR levels
(bands 1–6) did not differ between IBS patients and HC (Figure 4b), whereas bands 1, 5, and 6 did.
B7-2 levels were found to inversely correlate with IBS severity score (Figure 4c).
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an increase in disease severity resulting in decreased B7-2 levels. 
Table 1. Characteristics of IBS and healthy controls (HC). 
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 (n = 15) (n = 15) (n = 15) (n = 15) 
Age (years) 27.2 ± 1.613 27.07 ± 3.113 27.53 ± 1.756 27.47 ± 1.082 
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Severity (n) 
    
Mild 4 2   
Moderate 8 9   
Severe 3 4   
4. Discussion 
We report several novel observations. First, stress receptors and CRFR are secreted and are 
present in murine and human plasma. CRF receptors are G protein-coupled receptors (GPCRs) and 
our report is the first to show presence of GPCRs in circulation. Second, while B7-2+ and CD-9+ EVs 
might be secreted from several sources, the important finding is that B7-2+ EVs levels and CRFR 
levels show a strong association in human plasma samples, whereas no association was found with 
CD-9+ EV. Third, B7-2+, CD9+, and CRFR band compositions in plasma is similar to that in purified 
EVs, thereby allowing for retrospective detection of EVs in already collected plasma samples.  
CRFRs overlap with EVs potentially secreted from immune cells such as mast cells, B cells, and 
dendritic cells. Mast cell dysfunction is thought to be involved in modulating visceral 
Figure 4. (a) Quantification of CRF-RI/II band 1 fro i unoblots using plas a of healthy controls
(HC) and IBS patients (n = 15/group). Two-way ANOVA showed significant main effect of IBS
(p = 0.0006), but not sex, and no interaction between IBS (disease) and sex was noted. CRFR Band
1 levels increased in male and female IBS patients compared with male HC (Sidak’s multiple
comparisons test; n = 15/group). Male IBS vs. Male HC, p = 0.028 and Female IBS vs. Male HC,
p = 0.0108. (b) Quantification of CRFR Bands 1–6 (total bands) from immunoblots from plasma of
healthy controls (HC) and IBS patients (n = 15/group). Two-way ANOVA showed no significant main
effect of IBS or sex. No significant difference in total CRFR levels between IBS and HC were noted. (c)
Linear regression revealed a significant inverse association between IBS-SS and B7-2 band 5 (p = 0.0492)
with an increase in disease severity resulting in decreased B7-2 levels.
Table 1. Characteristics of IBS and healthy controls (HC).
Male IBS Female IBS Male HC Female HC
(n = 15) (n = 15) (n = 15) (n = 15)
Age (years) 27.2 ± 1.613 27.07 ± 3.113 27.53 ± 1.756 27.47 ± 1.082
IBS-SS 221.2 ± 17.47 246.3 ± 15.92
Usual Severity (n)
Mild 4 2
Moderate 8 9
Severe 3 4
4. Discussion
We report several novel observations. First, stress receptors and CRFR are secreted and are present
in murine and human plasma. CRF receptors are G protein-coupled receptors (GPCRs) and our report
is the first to show presence of GPCRs in circulation. Second, while B7-2+ and CD-9+ EVs might be
secreted from several sources, the important finding is that B7-2+ EVs levels and CRFR levels show
a strong association in human plasma samples, whereas no association was found with CD-9+ EV.
Third, B7-2+, CD9+, and CRFR band compositions in plasma is similar to that in purified EVs, thereby
allowing for retrospective detection of EVs in already collected plasma samples.
CRFRs overlap with EVs potentially secreted from immune cells such as mast cells, B cells,
and dendritic cells. Mast cell dysfunction is thought to be involved in modulating visceral
hypersensitivity in IBS patients. CRFR levels were significantly higher in plasma of IBS patients
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compared with HC, and were significantly associated with IBS severity. Presence of GPCRs
in circulation opens up the possibility for more nuanced modulation of signaling via these
receptors. While in vitro studies that use transfected GPCRs have shown the presence of GPCRs
in exosomes [5,43], presence of GPCRs in EVs from in vivo samples had not been demonstrated.
These published studies showed that, in cultured cells, GPCRs can be transferred by exosomes from
a source cell to a target cell and maintain functionality. Our in vivo data suggested that circulating
EVs are potential reservoirs for CRFRs and can be transported from multiple sources to several target
tissues for highly nuanced signaling and immune responses.
Several bands for CRF receptors were present in both human and mouse plasma in this study.
Crhr2 null mice express normal levels of CRF1, and the anti-CRF-RI/II antibodies that cross-reacts
with both CRF1 and CRF2 receptors detected multiple bands, as before [41]. CRFRs from different
organs are differentially post-translationally modified [44] resulting in several bands. Various bands
are also attributed to CRFRs heteromerization [41]. CRF2 receptor, but not CRF1 traffics to the
plasma membrane from endoplasmic reticulum in actin-dependent manner [41]. In light of the
findings that other GPCRs, such as somatostatin are sequestered into ectosomes from the cilia plasma
membrane [4], it is plausible that CRF2 expressed from the goblet cells in the gut may also be secreted
into ectosomes in actin-dependent manner. The observation that total CRFR levels (bands 1–6) did
not differ between IBS patients and HC (Figure 4B), whereas bands 1, 5, and 6 did, suggesting
to us that these CRFR bands harbor different modifications and may be secreted from different
sources/cell types. CRFR may be post-translationally modified differently in IBS patients compared
with HC. In agreement with this hypothesis, differential glycosylation of CRFR is reported in health
and disease [44]. CRFRs from specific sources contribute to variability in those band sizes and/or
are secreted in the plasma in either free-form or in EVs. In support of this notion, a recent study
reported that cytokines secreted from the placental villous are largely soluble, whereas those secreted
from T-cells, monocytes, and amnion are EV-associated [9]. Thus, blood and bodily fluids harbor a
heterogeneous mix of free and EV-associated cargo.
In light of our findings of a strong association of CRFRs with B7-2+, but not CD9+-containing EVs
in IBS patients and healthy controls, it would be interesting to further interrogate the composition of
B7-2+ EVs by co-immunoprecipitation followed by mass spectrometry. Specifically, mast cells, B cells,
and dendritic cells from IBS patients and healthy subjects can be sorted and purified B7-2+ EVs can be
characterized further. A study showed that glioma-derived exosomes exerted their effects on monocyte
maturation to suppress T-cell immune responses [45]. The cargo composition of these glioma-derived
exosome was not delineated, nonetheless, irrespective of the method used to isolate these exosomes,
the functional outcome was that the exosomes exerted their effect by acting on monocytes rather than
direct interaction with T cells [45]. Thus, the precise nature of EV-associated cargo that alters function,
has not been delineated. The paradoxical observation that higher CRFR levels are associated with
lower IBS severity scores suggests that CRFRs from immune cells are protective and as the disease
progresses, immune cells are unable to make sufficient CRFRs. Indeed, B7-2 levels were inversely
correlated with IBS severity score (Figure 4c). It is also possible that the composition of CRFR in EVs
between HC and IBS may differ. The lack of association between CRFRs and CD9+ intestinal EVs is
intriguing, but this does not rule out the possibility that CRFRs may still be subjected to differential
subcellular localization [15] or post-translational modification in the gut of IBS patients vs. HC.
5. Conclusions
Plasma CRFR and B7-2+ EVs in conjunction can serve as potential biomarkers for disease severity
in IBS-D patients. Further studies are needed to determine the association with other IBS subtypes and
to characterize CRFR-containing and B7-2+ EV composition.
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